07:00 , Oct 15, 2007 |  BC Week In Review  |  Clinical News

ARG098: Phase I start

By year end, Argenes will begin a dose-escalation, Japanese Phase I trial in patients. Argenes Inc., Tokyo, Japan   Product: ARG098   Business: Autoimmune   Molecular target: NA   Description: Anti-Fas IgM monoclonal antibody that specifically targets Fas...
07:00 , Oct 15, 2007 |  BC Week In Review  |  Clinical News

ARG098: Phase I started

Argenes began a Belgian Phase I trial to evaluate ARG098 injected into the patients' knee joint cavity. Argenes Inc., Tokyo, Japan   Product: ARG098   Business: Autoimmune   Molecular target: NA   Description: Anti-Fas IgM monoclonal antibody that...